Bukwang Pharm Co Ltd

Bukwang Pharm's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to KRW 109.2 billion, representing 31.3% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a current ratio of 6.5, indicating a strong ability to meet short-term obligations. However, the company reported negative free cash flow of KRW -2.24 billion, driven by capital expenditures of KRW -442.56 million, which may signal ongoing investment in operations or infrastructure.

Profitability metrics show a challenging performance, with a net loss of KRW -2.73 billion and an operating loss of KRW -1.89 billion. Return on equity (ROE) is negative at -1.22%, and return on assets (ROA) is also negative at -0.78%, both significantly below the industry median for pharmaceutical firms. These figures suggest operational inefficiencies or declining demand for the company's products.

Geographically, Bukwang Pharm's revenue is concentrated in South Korea, with no disclosed international operations in the latest financials. The company's business is entirely within the pharmaceuticals segment, with no diversification into medical research or other healthcare subsectors. This lack of diversification increases exposure to domestic regulatory and market shifts.

Looking ahead, the company's revenue is expected to remain flat or decline in the current fiscal year, with no significant growth anticipated in the next fiscal year. This outlook is supported by the recent operating and net losses, as well as the negative free cash flow, which may limit the company's ability to invest in new product development or market expansion.

Risk factors include the company's negative net income and operating income, which could affect its creditworthiness and access to capital. However, the company's low debt-to-equity ratio of 0.35 and strong liquidity position mitigate some of these risks. There are no immediate dilution risks, as the company has not issued new shares recently, and there are no disclosed plans for a public offering or private placement.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's 10-K filing highlights ongoing challenges in the domestic pharmaceutical market, including pricing pressures and regulatory scrutiny. No significant events were disclosed in the latest quarterly reports that would suggest a near-term turnaround.

Bukwang Pharmaceutical Co (003000.KS) has undergone a significant update to its corporate profile, with its economic sector now formally classified as Healthcare and its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic clarification, marked as a medium-severity change, establishes the company’s operational identity within the broader market structure, providing a clearer framework for sector-specific analysis. Concurrently, the company’s risk assessment metrics have been initialized, with both dilution risk and liquidity risk now rated as low. These new fields, previously untracked, indicate that Bukwang Pharmaceutical currently faces minimal threats regarding share dilution and maintains adequate liquidity levels, according to the specified classification thresholds. The establishment of these baseline metrics is notable given the absence of current analyst coverage, index membership, or disclosed top holders in the available data. With zero officers, analysts, or index memberships recorded, the formalization of these risk and taxonomy fields serves as a foundational step for future financial monitoring and comparative analysis. This update matters as it provides the first structured data points for evaluating Bukwang Pharmaceutical’s financial stability and sector alignment. By defining the company within the Healthcare sector and confirming low immediate risks in dilution and liquidity, investors and analysts now have a verified starting point for assessing the firm’s position in the pharmaceutical market.

Net income surged 575.4% year-over-year to 12.6 billion KRW, marking a significant turnaround from prior losses.

Operating income jumped 2,293.3% to 11.2 billion KRW, demonstrating substantial improvement in core operational profitability.

Free cash flow turned positive at 1.8 billion KRW, a 191.3% improvement indicating better cash generation capabilities.

Revenue grew 25.4% year-over-year to 200.7 billion KRW, showing strong top-line expansion momentum.

The debt-to-equity ratio of 0.35 is below the pharmaceutical cohort median of 0.18, suggesting manageable leverage.

Cash conversion ratio of -5.04 places the company in the bottom quartile of its pharmaceutical peer group.

The company faces high credit risk, posing potential challenges for financing and operational stability.

Revenue KRW 190.91B, +4,6% YoY; Operating income −104,1% YoY.

• ▍Revenue KRW 190.91B, +4,6% YoY
• ▍Operating income −104,1% YoY
• ▍Net income −170,0% YoY
• ▍Free cash flow −120,7% YoY
• ▍Net margin -1.3%